{"id": "367956", "url": "https://fevir.net/resources/Evidence/367956", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "26", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "name": "NCT03640312_otherOutcomeMeasure_4_OutcomeAnalysis_15_BetweenGroupAnalysis_OG000_OG001", "title": "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367956. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367956. Computable resource at: https://fevir.net/resources/Evidence/367956#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "statistic": [{"note": [{"text": "Outcome Analysis NonInferiority Type: Superiority"}], "quantity": {"unit": "mEq/L", "value": -0.71}, "statisticType": {"text": "Mean Difference (Net)"}, "attributeEstimate": [{"type": {"coding": [{"code": "STATO:0000037", "system": "https://fevir.net/sevco", "display": "standard error of the mean"}]}, "quantity": {"unit": "mEq/L", "value": 0.45}}, {"note": [{"text": "Linear mixed model. Random participant effects. Fixed baseline systolic, study arm, and time effects."}], "type": {"coding": [{"code": "C44185", "system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "display": "P-value"}]}, "quantity": {"value": 0.12}}, {"note": [{"text": "CI Number of Sides: 2-Sided"}], "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "code": "C53324", "display": "Confidence interval"}]}, "level": 0.95, "range": {"low": {"unit": "mEq/L", "value": -1.61}, "high": {"unit": "mEq/L", "value": 0.19}}}], "modelCharacteristic": [{"code": {"text": "Mixed Models Analysis"}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367956", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-4-OutcomeAnalysis-15-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol."}], "intended": {"type": "Group", "reference": "Group/367881", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "population"}, {"observed": {"display": "Group Assignment: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. vs. Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}, "description": "Group Assignment: QUARTET LDQT vs. Candesartan", "variableRole": "exposure", "comparatorCategory": "Candesartan"}, {"observed": {"type": "EvidenceVariable", "display": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367900", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}